Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry

BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). AIM: To evaluate effectiveness, safety and use of tofacitinib in daily practice. METHODS: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Cort...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Aliment Pharmacol Ther
Auteurs principaux: Biemans, Vince B. C., Sleutjes, Jasmijn A. M., de Vries, Annemarie C., Bodelier, Alexander G. L., Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van Bodegraven, Adriaan A., van der Meulen‐de Jong, Andrea E., de Boer, Nanne K. H., Srivastava, Nidhi, West, Rachel L., Römkens, Tessa E. H., Horjus Talabur Horje, Carmen S., Jansen, Jeroen M., van der Woude, C. Janneke, Hoekstra, Jildou, Weersma, Rinse K., van Schaik, Fiona D. M., Hoentjen, Frank, Pierik, Marieke J.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Tofacitinib for Ulcerative Colitis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187329/
https://ncbi.nlm.nih.gov/pubmed/32237087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15689
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires